Studies of the Effects of Estradiol, Progesterone, Cortisol, Thrombophlebitis, and Typhoid Vaccine on Synthesis and Catabolism of Antithrombin III in the Dog

Summary

Effects of estradiol, progesterone, Cortisol, thrombophlebitis and typhoid vaccine on the synthesis and catabolism of antithrombin III (AT) in dogs were studied, using I-125-labeled AT (I-125-AT) as a tracer. Five dogs were used for each study. A single intramuscular injection of 20 mg estradiol caused a 20% decrease of plasma AT concentration in 6 days without appreciable changes in the plasma half-lives of I-125-AT but with a significant decrease in the fractional catabolic rate of I-125-AT (j_3u). A single intramuscular injection of 250 mg progesterone did not produce any appreciable changes of plasma AT concentration, the plasma half-lives of I-125-AT or j_3u. On the other hand, intravenous and intramuscular injections of a total of 750 mg Cortisol caused a 17 % increase of plasma AT concentration in a day after the injections without alterations of the plasma half-lives of I-125-AT or j_3u. Next, thrombophlebitis was produced in dogs by a single intravenous injection of 1 ml 90% phenol into a leg vein occluded for 1 min by a gauze tourniquet and the effects of thrombophlebitis were studied. The results indicated that it did not cause appreciable changes of plasma AT concentration, the plasma half-lives of I-125-AT or j_3u. However, studies of the effects of a single intravenous injection of 3 ml typhoid vaccine showed a 25 % decrease of plasma AT concentration in a day after the injection with a moderate acceleration of the decline rate of plasma I-125-AT and a 14% increase in j_3u values. Further studies in heparinized dogs showed similar effects with typhoid vaccine. These results indicate that estradiol causes a decreased rate of AT synthesis, that progesterone has no appreciable effects on AT metabolism, that Cortisol increases the rate of AT synthesis, that localized thrombophlebitis has no appreciable effects on AT metabolism and that typhoid vaccine causes an increased j_3u by unknown mechanisms which is not an accelerated coagulation process.

• References

• 1 Abildgaard U. Purification of two progressive antithrombins of human plasma. Scandinavian Journal of Clinical and Laboratory Investigation 1967; 19: 190
• 2 Anderson M.M, Borg H, Anderson L.C. Purification of antithrombin III by affinity chromatography. Thrombosis Research 1974; 5: 439
• 3 Biggs R. Human Blood Coagulation, Haemostasis and Thrombosis . 1972. Blackwell Scientific Publications; Oxford, England:
• 4 Damus P.S, Wallace G.A. Purification of canine antithrombin III-heparin cofactor using affinity chromatography. Biochemical and Biophysical Research Communications 1974; 61: 1147
• 5 Davis B.J. Disc electrophoresis. II. Method and application to serum proteins. Annals of New York Academy of Sciences 1964; 121: 404
• 6 Fagerhol M.K, Abildgaard U, Bergsjo P. Oral contraceptives and low antithrombin III concentration. Lancet 1970; 1: 1175
• 7 Fagerhol M.K, Abildgaard U. Immunological studies on human antithrombin III. Influence of age, sex and use of oral contraceptives on serum concentrations. Scandinavian Journal of Hematology 1970; 7: 10
• 8 Hedlin A.M. The effect of oral contraceptive estrogen on blood coagulation and fibrinolysis. Thrombosis et Diathesis haemorrhagica 1975; 33: 370
• 9 von Kaulla E, von Kaulla K.N. Oral contraceptives and low antithrombin III activity. Lancet 1970; 1: 36
• 10 Kobayashi N, Takeda Y. Effects of estradiol on antithrombin III metabolism in male and female dogs. Europ. J. clin Invest. (in press) 1976
• 11 Kobayashi N, Takeda Y. Effects of estradiol on antithrombin III metabolism in the dog. Federation Proceedings 1976; 35: 756
• 12 McFarlane A.S. Efficient tracer labeling of proteins with iodine. Nature (London) 1958; 182: 53
• 13 McFarlane A.S. In vivo behavior of I-131-fibrinogen. Journal of Clinical Investigation 1963; 42: 346
• 14 Mink I.B, Courey N.G, Moore R.H, Ambrus C.M, Ambrus J.L. Progestational gents and blood coagulation. American Journal of Obstetrics and Gynecology 1972; 113: 739
• 15 Monkhouse F.G, France E.S, Seegers W.H. Studies on the antithrombin and heparin cofactor activities of a fraction adsorbed from plasma by aluminum hydroxide. Circulation Research 1955; 3: 397
• 16 Poller L, Thomson J.M, Tabiowo A, Priest C.M. Progesterone oral contraception and blood coagulation. British Medical Journal 1969; 1: 554
• 17 Reeve E.B, Roberts J.E. The kinetics of the distribution and breakdown of I-131-albumin in the rabbit. Journal of General Physiology 1959; 43: 415
• 18 Rosenberg R.D, Damus P.S. The purification and mechanism of action of human anti-thrombin-heparin cofactor. Journal of Biological Chemistry 1973; 248: 6490
• 19 Solomon A.K. The kinetics of biological processes. Special problems connected with the use of tracers. Advances in Biology, Medicine and Physics 1953; 3: 65
• 20 Takeda Y. Hormonal effects on distribution and excretion of iodine-I-131 in the dog. American Journal of Physiology 1964; 206: 1237
• 21 Takeda Y. Studies of the metabolism and distribution of fibrinogen in healthy men with autologous I-125-labeled fibrinogen. Journal of Clinical Investigation 1966; 45: 103
• 22 Takeda Y. Effects of typhoid endotoxin on fibrinogen and prothrombin metabolism in calves. In: Rothschild M.A, Waldmann T. (ed.) Plasma Protein Metabolism, Academic Press; New York: 1970: p. 443
• 23 Takeda Y. Plasminogen-I-125 responses in dogs to a single injection of urokinase and typhoid vaccine and to vascular injury. Journal of Clinical Investigation 1972; 51: 1363
• 24 Yin E.T, Wessler S, Stoll P.J. Rabbit plasma inhibitor of the activated species of blood coagulation factor X. Purification and some properties. Journal of Biological Chemistry 1971; 246: 3694
• 25 Yin E.T, Wessler S, Stoll P.J. Biological properties of the naturally occurring plasma inhibitor to activated factor X. Journal of Biological Chemistry 1971; 246: 3703